Your browser doesn't support javascript.
loading
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
Khanani, Arshad M; Zarbin, Marco A; Barakat, Mark R; Albini, Thomas A; Kaiser, Peter K; B, Guruprasad; Agashivala, Neetu; Yu, Justin S; Wykoff, Charles C; MacCumber, Mathew W.
Afiliación
  • Khanani AM; Sierra Eye Associates, Reno, Nevada.
  • Zarbin MA; Reno School of Medicine, University of Nevada, Reno.
  • Barakat MR; Institute of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School, Rutgers University, Newark, New Jersey.
  • Albini TA; Retinal Consultants of Arizona, Phoenix.
  • Kaiser PK; Bascom Palmer Eye Institute, Miami, Florida.
  • B G; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
  • Agashivala N; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Yu JS; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Wykoff CC; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • MacCumber MW; Retina Consultants of Texas, Houston.
JAMA Ophthalmol ; 140(1): 20-28, 2022 Jan 01.
Article en En | MEDLINE | ID: mdl-34817566

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Vasculitis Retiniana / Degeneración Macular Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: JAMA Ophthalmol Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Vasculitis Retiniana / Degeneración Macular Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: JAMA Ophthalmol Año: 2022 Tipo del documento: Article
...